ImmuCell (ICCC) Revenue & Revenue Breakdown


OverviewOwnershipFinancialsChartTranscripts

ImmuCell Revenue Highlights


Latest Revenue (Y)

$17.47M

Latest Revenue (Q)

$6.01B

Main Segment (Y)

FirstDefenseProductLineMember

Main Geography (Y)

FirstDefenseProductLineMember

ImmuCell Revenue by Period


ImmuCell Revenue by Year

DateRevenueChange
2023-12-31$17.47M-5.90%
2022-12-31$18.57M-3.51%
2021-12-31$19.24M25.43%
2020-12-31$15.34M11.80%
2019-12-31$13.72M24.91%
2018-12-31$10.99M5.32%
2017-12-31$10.43M9.29%
2016-12-31$9.54M-6.69%
2015-12-31$10.23M34.64%
2014-12-31$7.60M26.46%
2013-12-31$6.01M11.45%
2012-12-31$5.39M5.45%
2011-12-31$5.11M16.53%
2010-12-31$4.39M-2.72%
2009-12-31$4.51M-2.70%
2008-12-31$4.63M-23.65%
2007-12-31$6.07M26.41%
2006-12-31$4.80M-3.65%
2005-12-31$4.98M34.82%
2004-12-31$3.70M10.10%
2003-12-31$3.36M-45.72%
2002-12-31$6.18M-7.37%
2001-12-31$6.68M18.47%
2000-12-31$5.64M14.80%
1999-12-31$4.91M9.09%
1998-12-31$4.50M-2.17%
1997-12-31$4.60M4.55%
1996-12-31$4.40M-10.20%
1995-12-31$4.90M11.36%
1994-12-31$4.40M12.82%
1993-12-31$3.90M-

ImmuCell generated $17.47M in revenue during NA 2023, up -5.90% compared to the previous quarter, and up 159.04% compared to the same period a year ago.

ImmuCell Revenue by Quarter

DateRevenueChange
2024-09-30$6.01B109742.75%
2024-06-30$5.47M-24.59%
2024-03-31$7.26M42.42%
2023-12-31$5.10M-5.57%
2023-09-30$5.40M52.76%
2023-06-30$3.53M2.50%
2023-03-31$3.45M-11.87%
2022-12-31$3.91M-18.45%
2022-09-30$4.80M24.20%
2022-06-30$3.86M-35.64%
2022-03-31$6.00M10.21%
2021-12-31$5.44M5.70%
2021-09-30$5.15M13.39%
2021-06-30$4.54M10.58%
2021-03-31$4.11M9.73%
2020-12-31$3.74M0.55%
2020-09-30$3.72M25.51%
2020-06-30$2.97M-39.60%
2020-03-31$4.91M35.20%
2019-12-31$3.63M22.27%
2019-09-30$2.97M9.61%
2019-06-30$2.71M-38.56%
2019-03-31$4.41M50.17%
2018-12-31$2.94M36.37%
2018-09-30$2.15M-28.55%
2018-06-30$3.01M4.63%
2018-03-31$2.88M-8.04%
2017-12-31$3.13M56.26%
2017-09-30$2.00M14.60%
2017-06-30$1.75M-50.63%
2017-03-31$3.54M60.08%
2016-12-31$2.21M12.48%
2016-09-30$1.97M-17.15%
2016-06-30$2.38M-20.45%
2016-03-31$2.99M10.84%
2015-12-31$2.69M8.98%
2015-09-30$2.47M26.12%
2015-06-30$1.96M-36.79%
2015-03-31$3.10M40.64%
2014-12-31$2.21M24.58%
2014-09-30$1.77M14.96%
2014-06-30$1.54M-26.04%
2014-03-31$2.08M33.51%
2013-12-31$1.56M26.29%
2013-09-30$1.23M-9.64%
2013-06-30$1.37M-26.00%
2013-03-31$1.85M29.96%
2012-12-31$1.42M31.97%
2012-09-30$1.08M-8.37%
2012-06-30$1.18M-31.56%
2012-03-31$1.72M31.62%
2011-12-31$1.30M30.01%
2011-09-30$1.00M-19.56%
2011-06-30$1.25M-19.81%
2011-03-31$1.56M38.82%
2010-12-31$1.12M28.26%
2010-09-30$873.72K-19.04%
2010-06-30$1.08M-17.75%
2010-03-31$1.31M26.88%
2009-12-31$1.03M2.23%
2009-09-30$1.01M1.03%
2009-06-30$1.00M-31.48%
2009-03-31$1.46M17.13%
2008-12-31$1.25M35.04%
2008-09-30$924.00K11.82%
2008-06-30$826.30K-49.48%
2008-03-31$1.64M8.84%
2007-12-31$1.50M-

ImmuCell generated $6.01B in revenue during Q3 2024, up 109742.75% compared to the previous quarter, and up 170170.28% compared to the same period a year ago.

ImmuCell Revenue Breakdown


ImmuCell Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 21
FirstDefenseProductLineMember$18.93M
OtherAnimalHealthMember$309.88K

ImmuCell's latest annual revenue breakdown by segment (product or service), as of Dec 21: FirstDefenseProductLineMember (98.39%), and OtherAnimalHealthMember (1.61%).

Quarterly Revenue by Product

Product/ServiceDec 21Sep 21Jun 21Jun 18Mar 18
OtherAnimalHealthMember$40.59K$116.75K$68.86K--
FirstDefenseProductLineMember$5.40M$5.03M$4.47M--
First Defense Product Line---$2.88M$2.78M
Other Animal Health---$131.06K$100.32K

ImmuCell's latest quarterly revenue breakdown by segment (product or service), as of Dec 21: FirstDefenseProductLineMember (99.25%), and OtherAnimalHealthMember (0.75%).

ImmuCell Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 21
FirstDefenseProductLineMember$18.93M
OtherAnimalHealthMember$309.88K
UNITED STATES$16.62M
OtherStatesMember$2.62M

ImmuCell's latest annual revenue breakdown by geography, as of Dec 21: FirstDefenseProductLineMember (49.19%), UNITED STATES (43.19%), OtherStatesMember (6.81%), and OtherAnimalHealthMember (0.81%).

Quarterly Revenue by Country

CountrySep 24Jun 24Mar 24Sep 23Dec 21Sep 21Jun 21Jun 18Mar 18
UNITED STATES$5.22M$4.89M$6.34M$4.92M$4.46M$4.55M$4.03M--
FirstDefenseProductLineMember----$5.40M----
OtherStatesMember----$984.57K$599.83K$511.57K--
OtherAnimalHealthMember----$40.59K----
United States-------$2.54M$2.60M
Other States-------$470.41K$285.57K

ImmuCell's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (100.00%).

ImmuCell Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
LIPOLipella Pharmaceuticals$449.62M$80.38M
FENCFennec Pharmaceuticals$21.64M$6.97M
ICCCImmuCell$17.47M$6.01B
HCWBHCW Biologics$2.84M$426.42K
MNOVMediciNova$1.00M-
ANEBAnebulo Pharmaceuticals--
RZLTRezolute--
CVKDCadrenal Therapeutics--
TPSTTempest Therapeutics--
PTIXProtagenic Therapeutics-$50.29K

ICCC Revenue FAQ


What is ImmuCell’s yearly revenue?

ImmuCell's yearly revenue for 2023 was $17.47M, representing a decrease of -5.90% compared to 2022. The company's yearly revenue for 2022 was $18.57M, representing a decrease of -3.51% compared to 2021. ICCC's yearly revenue for 2021 was $19.24M, representing an increase of 25.43% compared to 2020.

What is ImmuCell’s quarterly revenue?

ImmuCell's quarterly revenue for Q3 2024 was $6.01B, a 109742.75% increase from the previous quarter (Q2 2024), and a 111297.63% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $5.47M, a -24.59% decrease from the previous quarter (Q1 2024), and a 54.92% increase year-over-year (Q2 2023). ICCC's quarterly revenue for Q1 2024 was $7.26M, a 42.42% increase from the previous quarter (Q4 2023), and a 110.58% increase year-over-year (Q1 2023).

What is ImmuCell’s revenue growth rate?

ImmuCell's revenue growth rate for the last 3 years (2021-2023) was -9.20%, and for the last 5 years (2019-2023) was 27.32%.

What are ImmuCell’s revenue streams?

ImmuCell's revenue streams in c 21 are FirstDefenseProductLineMember, and OtherAnimalHealthMember. FirstDefenseProductLineMember generated $18.93M in revenue, accounting 98.39% of the company's total revenue OtherAnimalHealthMember generated $309.88K in revenue, accounting 1.61% of the company's total revenue

What is ImmuCell’s main source of revenue?

For the fiscal year ending Dec 21, the largest source of revenue of ImmuCell was FirstDefenseProductLineMember. This segment made a revenue of $18.93M, representing 98.39% of the company's total revenue.